Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Share-based Compensation (2024 - 2025)

Maze Therapeutics has reported Share-based Compensation over the past 2 years, most recently at $6.1 million for Q4 2025.

  • Quarterly Share-based Compensation rose 113.01% to $6.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.4 million through Dec 2025, up 70.02% year-over-year, with the annual reading at $16.4 million for FY2025, 70.02% up from the prior year.
  • Share-based Compensation was $6.1 million for Q4 2025 at Maze Therapeutics, up from $3.9 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $6.1 million in Q4 2025 and troughed at $2.1 million in Q2 2024.